Hannah Katcoff1, Angela S Wenzlaff, Ann G Schwartz. 1. *Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan; and †Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.
Abstract
INTRODUCTION: Although lung cancer is the leading cause of cancer death in women, few studies have investigated the hormonal influence on survival after a lung cancer diagnosis and results have been inconsistent. We evaluated the role of reproductive and hormonal factors in predicting overall survival in women with non-small-cell lung cancer (NSCLC). METHODS: Population-based lung cancer cases diagnosed between November 1, 2001 and October 31, 2005 were identified through the Metropolitan Detroit Surveillance, Epidemiology, and End Results Registry. Interview and follow-up data were collected for 485 women. Cox proportional hazard regression models were used to determine hazard ratios (HRs) for death after an NSCLC diagnosis associated with reproductive and hormonal variables. RESULTS: Use of hormone therapy (HT) was associated with improved survival (HR, 0.69; 95% confidence interval, 0.54-0.89), adjusting for stage, surgery, radiation, education level, pack-years of smoking, age at diagnosis, race, and a multiplicative interaction between stage and radiation. No other reproductive or hormonal factor was associated with survival after an NSCLC diagnosis. Increased duration of HT use before the lung cancer diagnosis (132 months or longer) was associated with improved survival (HR, 0.54; 95% confidence interval, 0.37-0.78), and this finding remained significant in women taking either estrogen alone or progesterone plus estrogen, never smokers, and smokers. CONCLUSION: These findings suggest that HT use, in particular use of estrogen plus progesterone, and long-term HT use are associated with improved survival of NSCLC.
INTRODUCTION: Although lung cancer is the leading cause of cancer death in women, few studies have investigated the hormonal influence on survival after a lung cancer diagnosis and results have been inconsistent. We evaluated the role of reproductive and hormonal factors in predicting overall survival in women with non-small-cell lung cancer (NSCLC). METHODS: Population-based lung cancer cases diagnosed between November 1, 2001 and October 31, 2005 were identified through the Metropolitan Detroit Surveillance, Epidemiology, and End Results Registry. Interview and follow-up data were collected for 485 women. Cox proportional hazard regression models were used to determine hazard ratios (HRs) for death after an NSCLC diagnosis associated with reproductive and hormonal variables. RESULTS: Use of hormone therapy (HT) was associated with improved survival (HR, 0.69; 95% confidence interval, 0.54-0.89), adjusting for stage, surgery, radiation, education level, pack-years of smoking, age at diagnosis, race, and a multiplicative interaction between stage and radiation. No other reproductive or hormonal factor was associated with survival after an NSCLC diagnosis. Increased duration of HT use before the lung cancer diagnosis (132 months or longer) was associated with improved survival (HR, 0.54; 95% confidence interval, 0.37-0.78), and this finding remained significant in women taking either estrogen alone or progesterone plus estrogen, never smokers, and smokers. CONCLUSION: These findings suggest that HT use, in particular use of estrogen plus progesterone, and long-term HT use are associated with improved survival of NSCLC.
Authors: Nadiyah Kazmi; Diana C Márquez-Garbán; Lilia Aivazyan; Nalo Hamilton; Edward B Garon; Lee Goodglick; Richard J Pietras Journal: Lung Cancer Manag Date: 2012-12
Authors: Ann G Schwartz; Geoffrey M Prysak; Valerie Murphy; Fulvio Lonardo; Harvey Pass; Jan Schwartz; Sam Brooks Journal: Clin Cancer Res Date: 2005-10-15 Impact factor: 12.531
Authors: Rowan T Chlebowski; Garnet L Anderson; JoAnn E Manson; Ann G Schwartz; Heather Wakelee; Margery Gass; Rebecca J Rodabough; Karen C Johnson; Jean Wactawski-Wende; Jane Morley Kotchen; Judith K Ockene; Mary Jo O'Sullivan; F Allan Hubbell; Jason W Chien; Chu Chen; Marcia L Stefanick Journal: J Natl Cancer Inst Date: 2010-08-13 Impact factor: 13.506
Authors: Louise A Brinton; Gretchen L Gierach; Abegail Andaya; Yikyung Park; Arthur Schatzkin; Albert R Hollenbeck; Margaret R Spitz Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-04-05 Impact factor: 4.254
Authors: Apar Kishor Ganti; Abe E Sahmoun; Amit W Panwalkar; Ketki K Tendulkar; Anil Potti Journal: J Clin Oncol Date: 2005-11-28 Impact factor: 44.544
Authors: Alison L Van Dyke; Michele L Cote; Angie S Wenzlaff; Wei Chen; Judith Abrams; Susan Land; Craig N Giroux; Ann G Schwartz Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-06 Impact factor: 4.254
Authors: Alison L Van Dyke; Michele L Cote; Geoffrey Prysak; Gina B Claeys; Angie S Wenzlaff; Ann G Schwartz Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-01-09 Impact factor: 4.254
Authors: Yiyang Li; Cheng Huang; Tamar Kavlashvili; Abby Fronk; Yuping Zhang; Yang Wei; Donghai Dai; Eric J Devor; Xiangbing Meng; Kristina W Thiel; Kimberly K Leslie; Shujie Yang Journal: Am J Cancer Res Date: 2020-06-01 Impact factor: 6.166
Authors: Rowan T Chlebowski; Heather Wakelee; Mary Pettinger; Thomas Rohan; Jingmin Liu; Michael Simon; Hilary Tindle; Catherine Messina; Karen Johnson; Ann Schwartz; Margery Gass; Jean Wactawski-Wende Journal: Clin Lung Cancer Date: 2015-10-22 Impact factor: 4.785
Authors: Greta Bütepage; Peter Carlqvist; Johanna Jacob; Asbjørn Toft Hornemann; Simona Vertuani Journal: BMC Public Health Date: 2022-10-14 Impact factor: 4.135
Authors: Sophie Pilleron; Helen Gower; Maryska Janssen-Heijnen; Virginia Claire Signal; Jason K Gurney; Eva Ja Morris; Ruth Cunningham; Diana Sarfati Journal: BMJ Open Date: 2021-03-10 Impact factor: 2.692